Hologic (HOLX) Reports In-Line Q2 EPS; Lowers Rev Guidance, Maintains EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. TMUS
7. SPY
8. CVS
9. UNH
10. SBUX

Go back to Hologic (HOLX) Reports In-Line Q2 EPS; Lowers Rev Guidance, Maintains EPS

Hologic (HOLX) PT Lowered to $40 at RBC Capital

May 3, 2018 8:47 AM EDT

RBC Capital lowered its price target on Hologic (NASDAQ: HOLX) to $40.00 (from $44.00) while maintaining a Sector Perform rating.

... More

Hologic (HOLX) PT Lowered to $40.50 at Evercore ISI

May 3, 2018 7:37 AM EDT

Evercore ISI lowered its price target on Hologic (NASDAQ: HOLX) to $40.50 (from $42.50) while maintaining a Outperform rating.

... More

Hologic (HOLX) PT Lowered to $43 at Needham & Company; 'Ugly Write-Down for Aesthetics Business'

May 3, 2018 6:43 AM EDT

Needham & Company lowered its price target on Hologic (NASDAQ: HOLX) to $43.00 (from $50.00) while maintaining a Buy rating.

Analyst Mike Matson commented, " HOLX's F2Q18 revenue beat and EPS met consensus. But management lowered its FY18 revenue guidance due to Cynosure and... More

Canaccord Genuity Downgrades Hologic (HOLX) to Hold

May 3, 2018 4:40 AM EDT

Canaccord Genuity downgraded Hologic (NASDAQ: HOLX) from Buy to Hold with a price target of $39.00 (from $48.00).

Analyst Mark Massaro comments "We think HOLX may "figure it out," but we now believe the turnaround of Cynosure will take longer than we expected,... More